Your browser doesn't support javascript.
loading
Survival Outcomes Following Discontinuation of Ipilimumab and Nivolumab for Advanced Melanoma in a Population-based Cohort.
Ksienski, D; Truong, P T; Wai, E S; Croteau, N S; Chan, A; Patterson, T; Clarkson, M; Hackett, S; Irons, S; Lesperance, M.
Afiliación
  • Ksienski D; BC Cancer-Victoria, British Columbia, Canada; University of British Columbia, British Columbia, Canada. Electronic address: dksienski@bccancer.bc.ca.
  • Truong PT; BC Cancer-Victoria, British Columbia, Canada; University of British Columbia, British Columbia, Canada.
  • Wai ES; BC Cancer-Victoria, British Columbia, Canada; University of British Columbia, British Columbia, Canada.
  • Croteau NS; Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, British Columbia, Canada.
  • Chan A; University of British Columbia, British Columbia, Canada; BC Cancer-Surrey, British Columbia, Canada.
  • Patterson T; BC Cancer-Victoria, British Columbia, Canada.
  • Clarkson M; BC Cancer-Victoria, British Columbia, Canada.
  • Hackett S; BC Cancer-Victoria, British Columbia, Canada.
  • Irons S; BC Cancer-Victoria, British Columbia, Canada.
  • Lesperance M; Department of Mathematics and Statistics, University of Victoria, British Columbia, Canada.
Clin Oncol (R Coll Radiol) ; 33(12): e561-e569, 2021 12.
Article en En | MEDLINE | ID: mdl-34226113

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Nivolumab / Melanoma Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Middle aged Idioma: En Revista: Clin Oncol (R Coll Radiol) Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Nivolumab / Melanoma Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Middle aged Idioma: En Revista: Clin Oncol (R Coll Radiol) Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article
...